Cargando…
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
BACKGROUND: Anti-amyloid vaccines may offer a convenient, affordable, and accessible means of preventing and treating Alzheimer's disease. UB-311 is an anti–amyloid-β active immunotherapeutic vaccine shown to be well-tolerated and to have a durable antibody response in a phase 1 trial. This pha...
Autores principales: | Yu, Hui Jing, Dickson, Samuel P., Wang, Pei-Ning, Chiu, Ming-Jang, Huang, Chin-Chang, Chang, Chiung-Chih, Liu, Hope, Hendrix, Suzanne B., Dodart, Jean-Cosme, Verma, Ajay, Wang, Chang Yi, Cummings, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338203/ https://www.ncbi.nlm.nih.gov/pubmed/37392597 http://dx.doi.org/10.1016/j.ebiom.2023.104665 |
Ejemplares similares
-
UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
por: Wang, Chang Yi, et al.
Publicado: (2017) -
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
por: Nimmo, Jacqui T., et al.
Publicado: (2021) -
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
por: Yu, Hui Jing, et al.
Publicado: (2022) -
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2020) -
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2023)